Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

X Cao

Showing results (801-810 of 815) with videos related to

Pageof 82
Sort By:
Zhonghua Liu Xing Bing Xue Za Zhi = Zhonghua Liuxingbingxue Zazhi|October 9, 2018
[The Wuhan Twin Birth Cohort Study]S P Yang, J Z Zhao, H Mei, et al.
The Review of Scientific Instruments|September 29, 2023
A versatile control program for positioning and shooting targets in laser-plasma experimentsP J Wang, D H Wang, Y Gao, et al.
Zhonghua Yi Xue Za Zhi|June 25, 2023
[Long-term mortality risk of valvular heart disease adults over 35 years old in Chinese communities]R Q Gu, J Y Qiu, C Y Zheng, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|December 3, 2025
[Identifying risk factors for acute graft-versus-host disease in patients with acute myeloid leukemia undergoing haploidentical hematopoietic stem cell transplantation]D Feng, W Liang, J X Cao, et al.
Scientific Reports|November 10, 2020
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumorsAlexander B Zaslavsky, M P Adams, X Cao, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 25, 2016
Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approachesA M Udager, T-Y Liu, S L Skala, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 23, 2025
Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trialN Harbeck, S Modi, L Pusztai, et al.
Leukemia|January 19, 2017
Genetics of ancestry-specific risk for relapse in acute lymphoblastic leukemiaS E Karol, E Larsen, C Cheng, et al.
Physical Review Letters|October 4, 2012
N = 16 spherical shell closure in 24OK Tshoo, Y Satou, H Bhang, et al.
The Journal of Clinical Investigation|July 15, 2025
Organ-specific features of human kidney lymphatics are disrupted in chronic transplant rejectionDaniyal J Jafree, Benjamin J Stewart, Karen L Price, et al.
Pageof 82

Showing results (801-810 of 815) with videos related to

Sort By:
Pageof 82
Zhonghua Liu Xing Bing Xue Za Zhi = Zhonghua Liuxingbingxue Zazhi|October 9, 2018
[The Wuhan Twin Birth Cohort Study]S P Yang, J Z Zhao, H Mei, et al.
The Review of Scientific Instruments|September 29, 2023
A versatile control program for positioning and shooting targets in laser-plasma experimentsP J Wang, D H Wang, Y Gao, et al.
Zhonghua Yi Xue Za Zhi|June 25, 2023
[Long-term mortality risk of valvular heart disease adults over 35 years old in Chinese communities]R Q Gu, J Y Qiu, C Y Zheng, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|December 3, 2025
[Identifying risk factors for acute graft-versus-host disease in patients with acute myeloid leukemia undergoing haploidentical hematopoietic stem cell transplantation]D Feng, W Liang, J X Cao, et al.
Scientific Reports|November 10, 2020
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumorsAlexander B Zaslavsky, M P Adams, X Cao, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 25, 2016
Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approachesA M Udager, T-Y Liu, S L Skala, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 23, 2025
Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trialN Harbeck, S Modi, L Pusztai, et al.
Leukemia|January 19, 2017
Genetics of ancestry-specific risk for relapse in acute lymphoblastic leukemiaS E Karol, E Larsen, C Cheng, et al.
Physical Review Letters|October 4, 2012
N = 16 spherical shell closure in 24OK Tshoo, Y Satou, H Bhang, et al.
The Journal of Clinical Investigation|July 15, 2025
Organ-specific features of human kidney lymphatics are disrupted in chronic transplant rejectionDaniyal J Jafree, Benjamin J Stewart, Karen L Price, et al.
Pageof 82